Pro Share Advisors LLC Corvus Pharmaceuticals, Inc. Transaction History

Pro Share Advisors LLC

  • $39.7 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019
SELL
$3.29 - $8.94 $44,757 - $121,619
-13,604 Closed
0 $0
Q3 2018

Nov 14, 2018
SELL
$8.58 - $11.4 $4,212 - $5,597
-491 Reduced 3.48%
13,604 $117,000
Q2 2018

Aug 13, 2018
BUY
$9.42 - $13.73 $31,001 - $45,185
3,291 Added 30.46%
14,095 $155,000
Q1 2018

May 14, 2018
SELL
$7.48 - $11.53 $13,336 - $20,557
-1,783 Reduced 14.17%
10,804 $125,000
Q4 2017

Feb 14, 2018
BUY
$9.3 - $16.93 $117,059 - $213,097
12,587
12,587 $130,000

Others Institutions Holding CRVS

# of Institutions
73
Shares Held
30.4M
Call Options Held
1.06M
Put Options Held
84.3K
View Full List

About Corvus Pharmaceuticals, Inc.

CRVS Quotes by TradingView
  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $223M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email